Type to search

News

Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy at 63rd ASH Annual Meeting

Share
Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy at 63rd ASH Annual Meeting | Pharmtech Focus

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced preclinical data for GC502, an allogeneic chimeric antigen receptor (CAR) T cell therapy for the treatment of B-cell malignancies, will be presented as a virtual poster at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition as part of the “Cellular Immunotherapies: Basic and Translational” session on December 11, 2021 from 5:30 p.m.-7:30 p.m.(EST).

GC502 is a CD19/CD7 dual-directed, stand-alone off-the-shelf allogeneic CAR-T therapy for the treatment of B-cell malignancies developed on Gracell’s proprietary TruUCAR technology platform. The novel dual CAR design allows the CD19 CAR moiety to target malignant cells, while the CD7 CAR moiety is designed to suppress host versus graft (HvG) (rejection) response, enabling GC502 to be a stand-alone therapy. Preclinical results demonstrate robust anti-tumor efficacy and promising potential to suppress HvG disease without the need for additional immunosuppressive therapeutics.

TruUCAR is Gracell’s proprietary technology platform designed to generate high-quality allogeneic CAR-T therapies using T cells from non-HLA matched healthy donors, manufactured in large quantities as “off-the-shelf” products at a lower cost.

“Encouraging preclinical data with GC502 validates the functionality of dual CAR developed on our TruUCAR platform and highlights the potential of our proprietary off-the-shelf, stand-alone allogeneic therapies for a broad range of patients.” Said Dr. Xinxin Wang, Vice President, Research and Development at Gracell.

“GC502 displays strong anti-tumor potency and suppression of HvG response in the preclinical study. We look forward to further clinical development of GC502 and expanding our early-stage pipeline with more safe, effective and accessible cell therapies for tough to treat hematological malignancies.” Commented Dr. Lianjun Shen, Senior Vice President, Head of Research and Development at Gracell.

Details on the poster presentation are shown below:
2021 63rd ASH Annual Meeting and Exposition
Abstract 148500: Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies
Abstract Release Time: 9:00 a.m., November 4, 2021
Presentation Session: Cellular Immunotherapies: Basic and Translational
Poster Presentation Time: 5:30 p.m. – 7:30 p.m., December 11, 2021

Tags:

Companies in this post:

You Might also Like

Related Stories

Next Up